Equities Analysts Issue Forecasts for ZVRA FY2024 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Analysts at Roth Capital dropped their FY2024 earnings per share estimates for shares of Zevra Therapeutics in a research note issued to investors on Tuesday, November 12th. Roth Capital analyst J. Aschoff now anticipates that the company will earn ($1.95) per share for the year, down from their prior estimate of ($1.57). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.63) per share. Roth Capital also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.38) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.31) EPS, FY2026 earnings at $0.67 EPS, FY2027 earnings at $1.41 EPS and FY2028 earnings at $1.85 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 177.96%. The business had revenue of $4.45 million for the quarter, compared to the consensus estimate of $4.08 million. During the same period in the previous year, the company earned ($0.15) EPS.

ZVRA has been the topic of several other research reports. William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Roth Mkm increased their price target on Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Guggenheim initiated coverage on Zevra Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $20.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a report on Friday, October 11th. Finally, Canaccord Genuity Group decreased their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $21.00.

Zevra Therapeutics Stock Down 4.5 %

Shares of NASDAQ:ZVRA opened at $8.62 on Friday. Zevra Therapeutics has a 52-week low of $4.18 and a 52-week high of $9.21. The firm has a market capitalization of $453.57 million, a P/E ratio of -4.38 and a beta of 1.93. The stock has a 50 day moving average price of $8.03 and a 200-day moving average price of $6.49. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00.

Institutional Trading of Zevra Therapeutics

A number of hedge funds have recently bought and sold shares of the business. International Assets Investment Management LLC boosted its position in shares of Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after purchasing an additional 5,940 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in shares of Zevra Therapeutics during the 1st quarter worth $64,000. The Manufacturers Life Insurance Company lifted its position in Zevra Therapeutics by 15.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after acquiring an additional 2,452 shares during the last quarter. Hunter Associates Investment Management LLC purchased a new stake in Zevra Therapeutics in the third quarter valued at $92,000. Finally, XTX Topco Ltd purchased a new stake in Zevra Therapeutics in the third quarter valued at $94,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.